Nestlé Health Science and Enterome confirm microbiome-based allergy and IBD deal 25-Jul-2022 By Will Chu Nestlé Health Science and Enterome are to co-develop and commercialise a series of microbiome-based immunotherapies for food allergies and inflammatory bowel disease (IBD).